TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma

Antibodies against programmed cell death-1 (PD-1) have considerably changed the treatment for melanoma. However, many patients do not display therapeutic response or eventually relapse. Moreover, patients treated with anti-PD-1 develop immune-related adverse events that can be cured with anti-tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertrand, Florie, Montfort, Anne, Marcheteau, Elie, Imbert, Caroline, Gilhodes, Julia, Filleron, Thomas, Rochaix, Philippe, Andrieu-Abadie, Nathalie, Levade, Thierry, Meyer, Nicolas, Colacios, Céline, Ségui, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741628/
https://www.ncbi.nlm.nih.gov/pubmed/29273790
http://dx.doi.org/10.1038/s41467-017-02358-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741628/
https://www.ncbi.nlm.nih.gov/pubmed/29273790
http://dx.doi.org/10.1038/s41467-017-02358-7

Ejemplares similares